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Investigations on prostate inflammation-related disorders, including acute and chronic prostatitis, chronic pelvic pain syndrome,
benign prostate hyperplasia (BPH), and prostate cancer (PCa), are still ongoing to find new, accurate, and noninvasive biomarkers
for a differential diagnosis of those pathological conditions sharing some common macroscopic features. Moreover, an ideal
biomarker should be useful for risk assessment of prostate inflammation progression to more severe disorders, like BPH or PCa,
as well as for monitoring of treatment response and prognosis establishment in carcinoma cases. Recent literature evidence
highlighted that changes in the expression of transglutaminases, enzymes that catalyze transamidation reactions leading to
posttranslational modifications of soluble proteins, occur in prostate inflammation-related disorders. This review focuses on the
role specifically played by transglutaminases 4 (TG4) and 2 (TG2) and suggests that both isoenzymes hold a potential to be
included in the list of candidates as novel diagnostic biomarkers for the above-cited prostate pathological conditions.
1. Introduction
Prostate is classified as an immune-competent organ, being
populated by leukocytes, including stromal and intraepithelial
T and B lymphocytes, macrophages, and mast cells; notably,
the number of leukocytes increases with aging [1]. In retro-
spect, it is significant to note that reviews of immunobiological
studies of the prostate and patients with diseases thereof (the
latest of which is [2]), including observations and suggestion
of the existence of a local immunological system, i.e., “prostate
lymphoreticular system,” ergo “being classified as an immune-
competent organ” [1],weremade prior tomore contemporary
observations. In the last decades, clinical trials and epidemio-
logical observations have shown that prostate inflammation is
a common condition in aged men [3–5].
Prostate inflammation is classified through histological
evaluation of the amount of inflammatory cells and their
effect on prostate tissue [6]. The prostate inflammatory pro-
cess may be triggered through different molecular pathways
of the immune system, which are dysregulated secondarily
to different factors: infectious bacterial agents, viruses, or
other sexually transmitted microorganisms, urinary reflux,
aging, dietary factors, hormones, autoimmune response, or
a combination of these factors [1, 2, 7, 8].
Inflammation is typically distinguished as acute (neutro-
philic cell infiltrate) and chronic (mononuclear cell infiltrate)
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[9]. Prostate inflammation may become a chronic process
when the microorganism causing acute prostatitis is not
eradicated.
Chronic prostatitis (CP) is a clinical syndrome, affecting
10% of the male elderly population, characterized by lower
genitourinary tract and/or genital pain or discomfort and
by inflammatory cells in prostatic secretions [10]. It has also
been defined as CP/chronic pelvic pain syndrome (CP/CPPS)
since it is not always caused by an infection. The presence of
mononuclear inflammatory cells in the prostate is not diag-
nostic for CP/CPPS, and other inflammatory cells, such as
T-cells, are commonly detected [4].
Chronic inflammatory processes are accompanied by the
release of large amounts of proinflammatory cytokines, as
well as oxygen and nitrogen reactive species (ROS and
RNS). Oxidative stress plays a key role in the pathogenesis
of CP/CPPS [11]. Cell response to both inflammation and
oxidative stress involves the activation of transcription factor
nuclear factor-kappa B (NF-κB), leading to the upregulation
of genes encoding for proinflammatory cytokines, the levels
of which are further increased, as well as chemotactic factors
and growth factors [12]. Several evidences show the presence
of oxidative stress markers in the secretions of the genitouri-
nary tract in patients affected by prostate inflammation [11].
Notably, chronic prostate inflammation is a process that
could lead to the development of more severe prostatic disor-
ders, like benign prostatic hyperplasia and prostate cancer,
and also of the genitourinary tract [1, 2, 13–17].
Benign prostatic hyperplasia (BPH), the most common
urological disorder in 70-80-year-old men [18], is a chronic
progressive condition due to a nonmalignant propagation
of stromal and epithelial cells eventually leading to prostate
enlargement, associated with the development of nodules
and proliferative inflammatory atrophy [19]. The pathogene-
sis and progression mechanisms of BPH are still not well
characterized, but they likely involve several factors, i.e.,
changes in epithelial-stromal interactions, alterations of local
endocrine and autonomous nerve system, tissue damage, and
subsequent chronic tissue healing. Some authors have assim-
ilated BPH to an immune-mediated inflammatory disease
[13, 14, 20–22], others suggested a relationship between pros-
tatic inflammation and lower urinary tract symptoms
(LUTS) [3, 4] and/or other promotional factors common to
BPH and PCa [14].
Prostate cancer (PCa) is considered as a chronic disease
and the most prevalent cancer in the male population [23].
Epidemiological studies suggest that PCa is hormone-
dependent and is associated with inflammation, as sug-
gested by the detection of PCa susceptibility genes involved,
such as RNAseL, MSR1, TLR4, MIC1, PON1, BRCA2,
CHEK2, and OGG, which have a role in prostate carcino-
genesis, and also in the host response to infection, inflam-
mation, and oxidative stress [24, 25]. However, there is
not a clear evidence showing that a reduction of PCa inci-
dence and progression may be achieved through inhibition
of prostate inflammation [26].
In the last years, great efforts have been undertaken to
identify novel biomarkers that, alone or combined with the
calculation of risks for the progression of prostate inflamma-
tion to BPH or PCa, may reduce the need for unnecessary
biopsies, improve the stratification of low-risk patients,
and better predict the response to treatments. Moreover,
ideal biomarkers should also be able to accurately discrim-
inate between indolent and aggressive cancers and identify
men at high risk for developing PCa that require immedi-
ate treatment [27].
Several lines of evidence suggest that a key role in inflam-
matory processes and in the inflammation-induced progres-
sion of several types of cancers is played by transglutaminase
2 (TG2) or tissue transglutaminase. TG2 is an ubiquitous
member of the transglutaminase (TG) family of enzymes,
that catalyze calcium-dependent transamidation reactions
through the incorporation of amines to glutamine residues
(polyamination) or cross-linking of lysine residues to gluta-
mine residues, resulting in the formation of intra- and inter-
molecular, covalent ε-(γ-glutamyl)lysine isopeptide bonds
[28]. The involvement of TG2, and also transglutaminase
4 (TG4), another member of TGs that is uniquely distrib-
uted in the prostate gland, has been reported in BPH and
PCa [29–34].
This review will summarize available literature data on
biomarkers of prostate disorders and discuss the role of TG
isoforms as potentially novel diagnostic biomarkers of pros-
tate inflammation-related diseases.
2. Current Biomarkers of Prostate Disorders
The first biomarker of prostatitis condition was the white
blood cell (WBC) count in prostatic secretion, but then, it
was discarded due to its poor sensitivity [35]. The assessment
of serum levels of prostate specific antigen (PSA), a member
of the kallikrein gene family, is still carried out for PCa
screening, even though the classification of PSA as a PCa bio-
marker has become increasingly controversial due to the lack
of specificity [36]. Suspicious digital rectal examination
and/or a serumPSA level ≥ 4 0 ng/mL, usually considered as
criteria to prompt further evaluation for PCa [37], has been
the subject of increasingly false positives and overdiagnosis.
For instance, the increase of serum PSA levels has also been
correlated with the aggressiveness of histological inflamma-
tion [38]. The low specificity of this test may be due to the
presence of different PSA isoforms, since alternative splicing
and alternative polyadenylation lead to the formation of at
least 15 PSA transcripts, encoding for at least eight different
proteins [39]. An investigation about the changes of these
spliced variants in PCa is required for more specific PSA
screening tests. Notably, several alternatively spliced iso-
forms of other kallikreins (KLK2, KLK3, KLK11, and
KLK15) have been shown to be upregulated in PCa [40].
Chronic inflammation has been associated with the
severity of lower urinary tract symptoms (LUTS), higher
International Prostate Symptom Score (IPSS), and higher
prostate volume if compared to prostate in normal condi-
tions [41, 42]. Even though less invasive methods are used
to assess the risk of developing prostatic chronic inflamma-
tion, such as detection of circulating biomarkers or imaging,
the unique instrument to make a diagnosis of CP remains the
histological exam [6, 43]. In prostate biopsies, the Chronic
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Prostatitis Symptom Index (CPSI) is utilised to highlight
prostatitis-like symptoms, such as pain and burning sensa-
tion, dribbling and hesitant urination, urgency, or painful
ejaculations. In fact, the total CPSI score is significantly asso-
ciated with chronic inflammation. Moreover, patients with
CP/CPPS are evaluated with UPOINT (urinary, psychoso-
cial, organ-specific, infection, neurogenic, and tenderness)
categorization [44].
A further diagnostic feature is the presence of prostatic
calcifications, which increase progressively with aging, and
the incidence of which has significantly been associated with
greater inflammation and protracted symptoms in patients
with CPPS [45–47].
One of the most reliable prostatic inflammation markers
is the level of IL-8 in seminal plasma [48, 49], even in com-
parison with other cytokines [35, 50]. Another experimental
marker of prostatic inflammation is the urinary level of
inducible T-cell costimulator (ICOS) protein involved in cell
signaling, immune response, and cell proliferation, that has
been significantly associated with maximum uroflowmetry
and postvoid residual urine volume [41]. Furthermore, the
involvement of monocyte chemotactic protein-1 (MCP-1)
has been hypothesized in the pathogenesis of CP and BPH,
as its increase in prostatic secretions is associated with pros-
tate volume enlargement and the expression of the macro-
phage marker CD-68 [51, 52].
CP has also been associated with autoimmune responses
against prostate antigens, including prostatic acid phospha-
tase (PAP), prostate steroid-binding protein (PSBP), PSA,
and other antigens in prostate homogenates and seminal
plasma [53–55].
PCa may present with both aggressive and indolent
forms. Given that low-grade prostate cancer is clinically
insignificant and usually not associated with metastatic dis-
semination, a common practice for the management of
patients with “low risk” or “favorable risk” is active surveil-
lance. This practice is appropriate for men having PSA levels
lower than 10ng/mL and involves the periodic monitoring of
patients through serial PSA testing, digital rectal exam, and
biopsy sampling [56].
The hardest challenges in the clinical practice are the
right selection of patients eligible for biopsy intervention,
the differentiation of indolent tumors from those with an
unfavorable prognosis, and the early recognition of higher-
risk disease in patients initially diagnosed with low-risk dis-
ease and monitored by active surveillance. Current diagnos-
tic biomarkers of PCa include blood-based tests, such as
ProstateHealth Index® and 4K score®, other than PSA; urine
sample-based tests, i.e., prostate cancer antigen 3 (PCA3),
SelectMDx®, and ExoDx Prostate IntelliScore®; and tissue-
based tests (ConfirmMDx®, Oncotype®, Prolaris®, and Deci-
pher®) following biopsy, transurethral resection, or radical
prostatectomy [27].
3. Role of Transglutaminase 4 in
Prostate Disorders
Transglutaminase 4 (TG4) was discovered in the early 1990s
from a human prostate cDNA library [57]. Its physiological
role has firstly been defined in rodents as a regulator of cop-
ulatory plug formation [58], which is relevant for the fertili-
zation, as it allows the seminal fluid to be kept in the vagina
[59]. Via the incorporation of seminal proteins, such as uter-
oglobin, semenogelins, or polyamines, into sperm cell sur-
faces, TG4 suppresses sperm antigenicity in the female
genital tract [60–62]. The typical TG substrates, polyamines,
in particular putrescine, spermidine, and spermine, are
secreted by the prostate gland and released in the seminal
fluid. In mice and humans, seminal plasma is rich in spermi-
dine and spermine of prostatic origin which may regulate at
the urethra level the seminal clot formation during the ejacu-
latory process [58]. Seminal vesicles, thus even in secretions,
have demonstrated intermediate TG activity and low poly-
amine amount. Notably, the level of protein-bound poly-
amines in ventral and anterior prostate suggests a higher
extracellular activity of prostatic TG and polyamines. Fur-
thermore, Km values of rat prostate TG for all the poly-
amines confirm the regulatory role of polyamines in the
formation of the seminal clot [63]. Interestingly, the presence
of autoantibodies against TG4 in association with human
male infertility has recently been demonstrated, suggesting
that TG4 plays a key role in the fertilization competence of
spermatozoa [64, 65].
The role of TG4 in humans is still not well characterized.
Human TG4 is a secretory protein having an expression pat-
tern restricted to the prostate, where it has been found in
luminal epithelial cells. TG4 is released in the seminal fluid
and responds to androgen stimulation [66, 67]. In this
regard, evidence has been provided that the retinoic acid
receptor gamma (RAR-G) plays a major role in the regula-
tion of TGM4 and that the presence of the androgen receptor
(AR), but not its transcriptional transactivation activity, is
critical for TGM4 transcription [68].
It has been reported that some human prostate cancer
cell lines lack TG4 expression [66], even if a basal transcrip-
tional activity of the promoter was observed [69]. Results
from an analysis of TG4 transcripts in metastatic prostate
cancer specimens indicate that TG4 expression was reduced
in most of them [70]. The downregulation of TG4 expression
in prostate cancer was confirmed by histological analyses of
its distribution within sections from tumor-containing pros-
tatectomy specimens and needle biopsies. The staining was
restricted to luminal epithelial cells and not detected in basal
epithelial or stromal cells. Moreover, TG4 staining was
detected in high-grade prostatic intraepithelial neoplasia
specimens but not in prostate carcinoma cells [67].
Other data have shown that TG4 knockdown is corre-
lated with a lowered invasive ability of prostatic cancer cells
[71]. TG4 expression showed a relatively wide profile in dif-
ferent prostate cancer cell lines and was strongly induced in
the low invasive CA-HPV-10 prostate cancer cell line [71].
Thus, TG4 can be involved with the invasiveness of prostate
cancer cells. A similar result was reported by Jiang and
coworkers showing TGM4 overexpression in a human pros-
tate tumor compared to normal tissue and a higher expres-
sion in high-Gleason score tumors [31].
In a mouse prostate cancer model generated by deletion
of the prostate epithelium-specific tumor suppressor PTEN,
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TGM4 was rapidly downregulated and the dedifferentiation
of the prostatic epithelium was quicker than in organ-
confined human prostate cancers [72]. Other studies have
revealed that TG4 overexpression in prostatic cells increases
the adhesion of tumor cells to endothelial cells and decreases
the barrier function of the latter. Moreover, TG4 sensitizes
prostate cells to hepatocyte growth factor (HGF) [73].
These contradictory results may be explained taking into
account that different studies may have addressed their
efforts in the search for the classical TG4 form. However,
proteins obtained by an alternative splicing mechanism
acquire, in part, different structural and functional features
compared to the original proteins [74]. These modifications
are likely responsible for the failure of RT-PCR,Western blot,
and immunohistochemical techniques aimed at detecting the
classical TG4 form. Indeed, Cho and coworkers found four
mRNA variants (L, M1, M2, and S) in the prostatic tissue
of patients affected by BPH and PCa [32]. TG4-M1 and
TG4-M2 have different splicing sites but not nucleotide size.
Moreover, TG4-L, TG4-M1, and TG4-M2 have correct open
reading frames, whereas TG4-S has a truncated reading
frame (Figure 1(a)); however, the role of alternative splicing
variants in prostate tissue is not well known.
Notably, TG4-M and TG4-S were detected in all tested
BPH and PCa prostate tissues, while TG4-L was found in
56% of BPH and only in 15% of PCa. These findings suggest
that changes in alternative splicing correlate with the devel-
opment of PCa. However, TG4-L expression did not corre-
late with PSA serum levels, prostate volumes, or PSA
densities [32]. Interestingly, although TG4 expressed in HeLa
cells has been found as a secreted protein, TG4-L has not
been detected in the supernatant of cell cultures [32].
The different cellular localizations suggest a different role
for the spliced variants since they likely use different protein
substrates, raising the idea that TG4 splicing variants may be
exploited as diagnostic and/or therapeutic targets, as seen
before for other genes in several cancers [75].
TGM4 expression levels were lower in moderately or
poorly differentiated carcinoma compared with normal tis-
sue [76]. Western blot analysis together with immunohisto-
chemical analysis demonstrated TGM4 downregulation in
prostate cancer [77]. Then, the comparison of protein
markers in prostatic secretions of men having organ-
confined tumors or extracapsular tumors showed differential
expression of TG4, PSA, ANXA3, and matrix metallopro-
teinases (MMP7 and 9) between the two groups [78].
TG4 resulted also to be involved in cancer disease pro-
gression via promotion of epithelial-mesenchymal transition
(EMT). In fact, in prostate epithelia-derived cancer cells, loss
of E-cadherin, acquisition of N-cadherin, and cell migration
have been highlighted [79].
4. Role of Transglutaminase 2 in
Prostate Disorders
TG2 is a multifunction protein, since other than acting as a
transamidating enzyme, it also displays GTPase, protein
disulfide isomerase, kinase, cell adhesion, and scaffolding
activities [80].
The function of TG2 in prostate is not fully under-
stood yet. Unlike the prostate-specific TG4, TG2 is ubiqui-
tous in prostatic tissue and is predominantly present in
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Figure 1: TG4 and TG2 alternative splicing. (a) Alternative splicing in TG4 transcript occurs at the N-terminal domain, leading to the
formation of three variants. The asterisks indicate the exon interested by the splicing mechanism for each variant. (b) The sequence
corresponding to the catalytic core or to the β-barrel domains of TG2 is involved in the splicing events. The intron retention mechanism
that leads to the formation of TG2_v2 affects the exon 10. Shown here is the GTP/GDP binding site that involves also few amino acids
(aa) in the exon 4 (arrow). In yellow is the conserved sequence of the catalytic core, including the cysteine (in bold).
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the intracellular compartment [57, 81]. Likely, TG2 is a
pivotal component of cell signaling because it modulates
the activation of the alpha1-adrenergic receptor, which medi-
ates prostatic smooth muscle contraction [82].
Numerous inflammatory cytokines and growth factors
stimulate TG2 expression, such as IL-1, IL-6, TNF-α, and
TGF-β [83–85], due to the presence in TGM2 gene promoter
of different regulatory sites for inflammatory modulators,
NF-κB response element (-1338 bp), IL-6 specific cis-regula-
tory element (-1190 bp), and TGF-β1 response element
(-868 bp). TG2 overexpression, in turn, has been reported
to constitutively activate and extend NF-κB activation
through IκBα polymerization and degradation (Figure 2), in
chronic inflammatory conditions and in cancer cells [86–88].
TG2 protein and mRNA expression have been evaluated
in experimental models of castration-induced prostatic atro-
phy with subsequent testosterone-induced prostatic hyper-
plasia. TG2 protein was strongly expressed and correlated
with apoptosis. TG2 mRNA levels were not affected during
the process of prostate involution but increased early in asso-
ciation with testosterone-induced proliferation [89]. Interest-
ingly, in men treated with finasteride, a 5 alpha-reductase
inhibitor, to reduce prostate size and ameliorate BPH symp-
toms, prostate involution has been shown to occur through
both atrophy and cell death processes, in which TG2 has been
demonstrated to play a relevant role [90].
Whey-acidic-protein four-disulfide core (WFDC) pro-
teins play a major role as regulators of innate immunity,
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Figure 2: Schematic of the alternative NF-κB activation pathway mediated by TG2. Inflammatory signals induce TG2 activation and
interaction with the cytosolic inactive NF-κB complex, composed of the transcriptionally active p50 and p65 subunits and the inhibitory
IκBα subunit. TG2 binding to IκBα leads to IκBα polymerization and release from NF-κB complex, followed by degradation of IκBα
aggregates via a proteasome-independent pathway. The active p50/p65 heterodimer complex, associated with TG2, translocates to the
nucleus where it binds to the NF-κB consensus sequence (GGGRNNYYCC) present in the promoter region of several genes involved in
inflammation as well as in tumorigenesis.
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antimicrobial function, and inhibition of inflammatory pro-
teases at mucosal surfaces. The prostate stromal 20 (ps20),
a protein of the WFDC family, is a potent growth inhibi-
tion factor, which is also able to modulate the wound heal-
ing process and immune response. It has recently been
shown that the posttranslational processing and cleavage
of ps20 are required to generate a functional protein spe-
cies and that TG2 mediates the cross-linking and cathep-
sin L cleavage to form components of a ps20 regulatory
apparatus [91].
Cancer cells have been reported to express elevated levels
of TG2; moreover, TG2 expression is further highly enriched
in cancer-derived stem cells and promotes their survival [92].
However, conflicting results have been reported about the
role of TG2 in PCa.
Despite the fact that TG2 was first suggested as a marker
of apoptosis during treatment and progression of PCa [29],
likely other mechanisms play a more relevant role in the
prostate. Birckbichler and coworkers suggested that if all epi-
thelial cells in prostate benign samples are immunoreactive
for TG2, it is possible that the TG2 main function is not the
promotion of apoptosis [93]. Interestingly, immunohisto-
chemistry analysis demonstrated that TG2 expression is
decreased in malignant glands as compared with benign or
hyperplastic glands [93]. This study suggested the potential
use of TG2 loss in prostate tissue as a potential biomarker
for differentiation of PCa from BPH or other inflammatory
conditions. Other than for diagnosis, the determination of
TG2 levels could be useful for individual risk assessment
and patient monitoring [93].
On the other hand, a strong interaction between protein
kinase A anchor protein 13 (AKAP13) and TG2 has been
reported in prostate cancer. Since AKAP plays a major role
in protein kinase A and Rho protein-mediated signaling,
the TG2-AKAP13 interaction has been suggested to play a
role in prostate cancer [30].
Advanced prostate cancer is often associated with
reduced androgen receptor (AR) expression leading to
castration-resistant cancer [94]. In the physiological response
to androgens, the AR binds to androgen-response elements
(AREs) to modulate gene transcription. The transcription
factor Oct1 is a context-dependent negative coregulator
of AR. Notably, siRNA knockdown of Oct1 increases the
transcription of TGM2, an endogenous AR target gene.
Therefore, Oct1 may have regulatory functions in prostate
development and cancer progression [95]. Recent studies
demonstrated high TG2 basal levels in advanced prostate
tumor cells showing a reduced AR expression. Notably,
TG2 was shown to negatively regulate the AR level. In partic-
ular, TG2-mediated NF-κB activation is able to induce NF-
κB binding to DNA elements in the AR gene, which in turn
reduces AR gene expression [34].
Recently, an interesting role of TGM2_v2 (according to
rationalized nomenclature [96]) or TG2 short form has been
highlighted in prostate cell lines or specimens. TGM2_v2
mRNA is obtained from an alternative splicing event with
an intron retention mechanism of intron X, and it encodes
for a 548 aa (63 kDa) protein. The loss of a portion of the
C-terminal domain (Figure 1(b)) decreases affinity for GTP,
resulting in the escape from the negative control mediated
by GTP on TG activity when there is a transient Ca2+
increase [97]. Interestingly, it has been reported that canoni-
cal and alternative TG2 isoforms are all expressed in normal
human prostate tissue, even if the relative amount of TGM2
shorter transcript is small compared with a full-length one
(TGM2_v2 10% vs. 90% TGM2_v1). Alternative splicing of
TGM2 occurs differently in cancer cell lines, and in prostate
cancer cells the alternative splicing of TG2 is a more active
process. Indeed, the average expression levels of TGM2_v2
were found to be higher than that of the long classic tran-
script (TGM2_v1) in a small screening of prostate cancer tis-
sues compared with normal tissues [96].
On the other hand, the differentiation treatment with
γ-tocopherol of prostate carcinoma PC3 cells induced a
decrease in the progression into the S-phase, which was asso-
ciated with TG2 upregulation and increased activity, signifi-
cant decrease of DNA synthesis, and protein expression of
cyclins D1 and E. TG2 upregulation and activation could be
part of a larger pathway that promotes the attenuation of
prostate cancer malignancy [98].
5. Conclusions
In the last years, evidence has been provided that human TG4
and TG2 are alternatively spliced in prostate tissues and that
alternative splicing processes occur in association with loss of
prostate tissue homeostasis and transition towards patholog-
ical states, i.e., inflammatory conditions and cancer. This
issue needs to be carefully addressed and become object of
further investigations aimed at better understanding whether
differential alternative splicing may represent a signature of
specific prostate disorders. In fact, results from these investi-
gations would open new diagnostic perspectives, particularly
if TG4 and TG2, and their alternative variants, could be
detected in serum samples from patients.
It is well known that TG4 is released in seminal plasma.
Although the presence of TG4 in serum has not been inves-
tigated, the detection of autoantibodies against TG4 in the
serum of male patients affected by infertility [64] suggests
that TG4 could also move from seminal plasma to serum. If
this was confirmed, the detection of TG4 and its alternatively
spliced forms in the serum of patients with prostate disorders
could be helpful in discriminating between prostate benign
inflammatory conditions and malignant conditions. How-
ever, if the TG4 presence was only restricted to seminal
plasma, the assessment of different TG4 variants in seminal
plasma could be helpful for diagnostic purposes and repre-
sent an alternative to biopsy intervention.
TG2 is known to be exported outside the cells, and this
event has been reported in inflammatory as well as malignant
conditions [80]. However, its presence in the seminal plasma
and serum has not yet been investigated. Given that TG2
autoantibodies are abundantly present in the serum of
patients affected by celiac disease [99], it is not unreasonable
to hypothesize that also TG2, and likely its alternatively
spliced variants, may be present either in serum or in seminal
plasma. The combined detection of TG4 and TG2 alternative
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variants in seminal plasma and serum could be a powerful
tool for differential diagnosis of prostate disorders.
Conflicts of Interest
The authors declare that they have no conflict of interest.
References
[1] A. M. DeMarzo, E. A. Platz, S. Sutcliffe et al., “Inflammation in
prostate carcinogenesis,” Nature Reviews Cancer, vol. 7, no. 4,
pp. 256–269, 2007.
[2] R. J. Ablin and T. C. Whyard, “Immunobiological implications
of selected bioactive molecules in the prostate with a known
and unknown target,” in The Prostate as an Endocrine Gland,
W. E. Farnsworth and R. J. Ablin, Eds., pp. 148–172, CRC
Press, 1990.
[3] J. C. Nickel, C. G. Roehrborn, M. P. O’Leary, D. G. Bostwick,
M. C. Somerville, and R. S. Rittmaster, “Examination of the
relationship between symptoms of prostatitis and histological
inflammation: baseline data from the REDUCE chemopreven-
tion trial,” The Journal of Urology, vol. 178, no. 3, pp. 896–901,
2007.
[4] J. C. Nickel, “Inflammation and benign prostatic hyperplasia,”
Urologic Clinics of North America, vol. 35, no. 1, pp. 109–115,
2008.
[5] C. A. St. Hill and M. N. Lutfiyya, “An epidemiological analysis
of potential associations between C-reactive protein, inflam-
mation, and prostate cancer in the male US population using
the 2009-2010 National Health and Nutrition Examination
Survey (NHANES) data,” Frontiers in Chemistry, vol. 3,
p. 55, 2015.
[6] D. M. Moreira, D. M. de O Freitas, J. C. Nickel, G. L. Andriole,
R. Castro-Santamaria, and S. J. Freedland, “The combination
of histological prostate atrophy and inflammation is associated
with lower risk of prostate cancer in biopsy specimens,” Pros-
tate Cancer and Prostatic Diseases, vol. 20, no. 4, pp. 413–417,
2017.
[7] G. Penna, B. Fibbi, S. Amuchastegui et al., “Human benign
prostatic hyperplasia stromal cells as inducers and targets of
chronic immuno-mediated inflammation,” Journal of Immu-
nology, vol. 182, no. 7, pp. 4056–4064, 2009.
[8] G. Penna, B. Fibbi, M. Maggi, and L. Adorini, “Prostate auto-
immunity: from experimental models to clinical counter-
parts,” Expert Review of Clinical Immunology, vol. 5, no. 5,
pp. 577–586, 2009.
[9] J. Irani, P. Levillain, J. M. Goujon, D. Bon, B. Dore, and
J. Aubert, “Inflammation in benign prostatic hyperplasia: cor-
relation with prostate specific antigen value,” The Journal of
Urology, vol. 157, no. 4, pp. 1301–1303, 1997.
[10] J. N. Krieger and K. J. Egan, “Comprehensive evaluation and
treatment of 75 men referred to chronic prostatitis clinic,”
Urology, vol. 38, no. 1, pp. 11–19, 1991.
[11] A. U. Ihsan, F. U. Khan, P. Khongorzul et al., “Role of oxidative
stress in pathology of chronic prostatitis/chronic pelvic pain
syndrome and male infertility and antioxidants function in
ameliorating oxidative stress,” Biomedicine & Pharmacother-
apy, vol. 106, pp. 714–723, 2018.
[12] G. Paulis, “Inflammatory mechanisms and oxidative stress in
prostatitis: the possible role of antioxidant therapy,” Research
and Reports in Urology, vol. 10, pp. 75–87, 2018.
[13] G. Kramer and M. Marberger, “Could inflammation be a key
component in the progression of benign prostatic hyperpla-
sia?,” Current Opinion in Urology, vol. 16, no. 1, pp. 25–29,
2006.
[14] R. J. Ablin, “Immunological aspects of benign prostatic hyper-
trophy,” in Benign Prostatic Hypertrophy, F. Hinman and S.
Boyarsky, Eds., pp. 73–98, Springer, New York, NY, USA,
1983.
[15] V. C. Mishra, D. J. Allen, C. Nicolaou et al., “Does intrapro-
static inflammation have a role in the pathogenesis and pro-
gression of benign prostatic hyperplasia?,” BJU International,
vol. 100, no. 2, pp. 327–331, 2007.
[16] K. C. Torkko, R. S. Wilson, E. E. Smith, J. W. Kusek, A. van
Bokhoven, andM. S. Lucia, “Prostate biopsy markers of inflam-
mation are associated with risk of clinical progression of benign
prostatic hyperplasia: findings from the MTOPS study,” The
Journal of Urology, vol. 194, no. 2, pp. 454–461, 2015.
[17] M. B. Frungieri, R. S. Calandra, A. Bartke, and M. E. Matzkin,
“Ageing and inflammation in the male reproductive tract,”
Andrologia, vol. 50, no. 11, article e13034, 2018.
[18] G. Kramer, D. Mitteregger, and M. Marberger, “Is benign
prostatic hyperplasia (BPH) an immune inflammatory dis-
ease?,” European Urology, vol. 51, no. 5, pp. 1202–1216, 2007.
[19] W. Bushman, “Etiology, epidemiology, and natural history,”
Urologic Clinics of North America, vol. 36, no. 4, pp. 403–
415, 2009.
[20] G. Kramer, G. E. Steiner, A. Handisurya et al., “Increased
expression of lymphocyte-derived cytokines in benign hyper-
plastic prostate tissue, identification of the producing cell
types, and effect of differentially expressed cytokines on stro-
mal cell proliferation,” Prostate, vol. 52, no. 1, pp. 43–58, 2002.
[21] G. E. Steiner, U. Stix, A. Handisurya et al., “Cytokine expres-
sion pattern in benign prostatic hyperplasia infiltrating T cells
and impact of lymphocytic infiltration on cytokine mRNA
profile in prostatic tissue,” Laboratory Investigation, vol. 83,
no. 8, pp. 1131–1146, 2003.
[22] G. E. Steiner, M. E. Newman, D. Paikl et al., “Expression and
function of pro-inflammatory interleukin IL-17 and IL-17
receptor in normal, benign hyperplastic, and malignant pros-
tate,” Prostate, vol. 56, no. 3, pp. 171–182, 2003.
[23] R. L. Siegel, K. D. Miller, and A. Jemal, “Cancer statistics,
2016,” CA: A Cancer Journal for Clinicians, vol. 66, no. 1,
pp. 7–30, 2016.
[24] W. G. Nelson, A. M. De Marzo, and W. B. Isaacs, “Prostate
cancer,” The New England Journal of Medicine, vol. 349,
no. 4, pp. 366–381, 2003.
[25] A. Alcaraz, P. Hammerer, A. Tubaro, F. H. Schroder, and
R. Castro, “Is there evidence of a relationship between benign
prostatic hyperplasia and prostate cancer? Findings of a litera-
ture review,” European Urology, vol. 55, no. 4, pp. 864–875,
2009.
[26] C. De Nunzio, G. Kramer, M. Marberger et al., “The contro-
versial relationship between benign prostatic hyperplasia and
prostate cancer: the role of inflammation,” European Urology,
vol. 60, no. 1, pp. 106–117, 2011.
[27] A. Carneiro, P. Priante Kayano, Á. R. Gomes Barbosa et al.,
“Are localized prostate cancer biomarkers useful in the clinical
practice?,” Tumor Biology, vol. 40, no. 9, 2018.
[28] M. Griffin, R. Casadio, and C. M. Bergamini, “Transglutami-
nases: nature’s biological glues,” Biochemical Journal, vol. 368,
no. 2, pp. 377–396, 2002.
7Mediators of Inflammation
[29] R. S. Rittmaster, L. N. Thomas, A. S. Wright et al., “The utility
of tissue transglutaminase as a marker of apoptosis during
treatment and progression of prostate cancer,” The Journal of
Urology, vol. 162, no. 6, pp. 2165–2169, 1999.
[30] T. E. Lewis, T. D. Milam, D. W. Klingler et al., “Tissue trans-
glutaminase interacts with protein kinase A anchor protein
13 in prostate cancer,” Urologic Oncology, vol. 23, no. 6,
pp. 407–412, 2005.
[31] W. Jiang, R. Ablin, H. Kynaston, and M. Mason, “Expression
of the prostate type transglutaminase (TGase-4) in clinical
prostate cancer,” Cancer Research, vol. 67, no. 9, pp. 2659–
2659, 2007.
[32] S.-Y. Cho, K. Choi, J. H. Jeon et al., “Differential alternative
splicing of human transglutaminase 4 in benign prostate
hyperplasia and prostate cancer,” Experimental and Molecular
Medicine, vol. 42, no. 4, pp. 310–318, 2010.
[33] W. G. Jiang and R. J. Ablin, “Prostate transglutaminase: a
unique transglutaminase and its role in prostate cancer,” Bio-
markers in Medicine, vol. 5, no. 3, pp. 285–291, 2011.
[34] A. L. Han, S. Kumar, J. Y. Fok, A. K. Tyagi, and K. Mehta,
“Tissue transglutaminase expression promotes castration-
resistant phenotype and transcriptional repression of andro-
gen receptor,” European Journal of Cancer, vol. 50, no. 9,
pp. 1685–1696, 2014.
[35] L. Liu, Q. Li, P. Han et al., “Evaluation of interleukin-8 in
expressed prostatic secretion as a reliable biomarker of inflam-
mation in benign prostatic hyperplasia,”Urology, vol. 74, no. 2,
pp. 340–344, 2009.
[36] M. R. Haythorn and R. J. Ablin, “Prostate-specific antigen test-
ing across the spectrum of prostate cancer,” Biomarkers in
Medicine, vol. 5, no. 4, pp. 515–526, 2011.
[37] W. J. Catalona, D. S. Smith, T. L. Ratliff et al., “Measurement of
prostate-specific antigen in serum as a screening test for pros-
tate cancer,”New England Journal of Medicine, vol. 324, no. 17,
pp. 1156–1161, 1991.
[38] L. Song, Y. Zhu, P. Han et al., “A retrospective study:
correlation of histologic inflammation in biopsy specimens
of Chinese men undergoing surgery for benign prostatic
hyperplasia with serum prostate-specific antigen,” Urology,
vol. 77, no. 3, pp. 688–692, 2011.
[39] N. Heuzé-Vourc'h, V. Leblond, and Y. Courty, “Complex
alternative splicing of the hKLK3 gene coding for the tumor
marker PSA (prostate-specific-antigen),” European Journal of
Biochemistry, vol. 270, no. 4, pp. 706–714, 2003.
[40] M. A. Reynolds, “Molecular alterations in prostate cancer,”
Cancer Letters, vol. 271, no. 1, pp. 13–24, 2008.
[41] G. Robert, F. Smit, D. Hessels et al., “Biomarkers for the diag-
nosis of prostatic inflammation in benign prostatic hyperpla-
sia,” Prostate, vol. 71, no. 15, pp. 1701–1709, 2011.
[42] J. C. Nickel, C. G. Roehrborn, M. P. O'Leary, D. G. Bostwick,
M. C. Somerville, and R. S. Rittmaster, “The relationship
between prostate inflammation and lower urinary tract symp-
toms: examination of baseline data from the REDUCE trial,”
European Urology, vol. 54, no. 6, pp. 1379–1384, 2008.
[43] R. Bardan, R. Dumache, A. Dema, A. Cumpanas, and
V. Bucuras, “The role of prostatic inflammation biomarkers
in the diagnosis of prostate diseases,” Clinical Biochemistry,
vol. 47, no. 10-11, pp. 909–915, 2014.
[44] R. C. Doiron, D. A. Tripp, V. Tolls, and J. C. Nickel, “The
evolving clinical picture of chronic prostatitis/chronic pelvic
pain syndrome (CP/CPPS): a look at 1310 patients over 16
years,” Canadian Urological Association Journal, vol. 12,
no. 6, pp. 196–202, 2018.
[45] E. Bock, V. Calugi, V. Stolfi, P. Rossi, R. D'Ascenzo, and F. M.
Solivetti, “Calcifications of the prostate: a transrectal echo-
graphic study,” La Radiologia Medica, vol. 77, no. 5, pp. 501–
503, 1989.
[46] S. E. Lee, J. A. H. Ku, H. K. Park, C. K. H. Jeong, and S. H. Kim,
“Prostatic calculi do not influence the level of serum prostate
specific antigen in men without clinically detectable prostate
cancer or prostatitis,” The Journal of Urology, vol. 170, no. 3,
pp. 745–748, 2003.
[47] D. A. Shoskes, C.-T. Lee, D. Murphy, J. Kefer, and H. M.
Wood, “Incidence and significance of prostatic stones in men
with chronic prostatitis/chronic pelvic pain syndrome,” Urol-
ogy, vol. 70, no. 2, pp. 235–238, 2007.
[48] P. Castro, C. Xia, L. Gomez, D. J. Lamb, and M. Ittmann,
“Interleukin-8 expression is increased in senescent prostatic
epithelial cells and promotes the development of benign pros-
tatic hyperplasia,” Prostate, vol. 60, no. 2, pp. 153–159, 2004.
[49] D. Giri and M. Ittmann, “Interleukin-8 is a paracrine inducer
of fibroblast growth factor 2, a stromal and epithelial growth
factor in benign prostatic hyperplasia,” The American Journal
of Pathology, vol. 159, no. 1, pp. 139–147, 2001.
[50] G. Penna, N. Mondaini, S. Amuchastegui et al., “Seminal
plasma cytokines and chemokines in prostate inflammation:
interleukin 8 as a predictive biomarker in chronic prostatitis/-
chronic pelvic pain syndrome and benign prostatic hyperpla-
sia,” European Urology, vol. 51, no. 2, pp. 524–533, 2007.
[51] K. Fujita, C. M. Ewing, R. H. Getzenberg, J. K. Parsons, W. B.
Isaacs, and C. P. Pavlovich, “Monocyte chemotactic protein-1
(MCP-1/CCL2) is associated with prostatic growth dysregula-
tion and benign prostatic hyperplasia,” The Prostate, vol. 70,
no. 5, pp. n/a–481, 2010.
[52] A. Latil, C. Libon, M. Templier, D. Junquero, F. Lantoine-
Adam, and T. Nguyen, “Hexanic lipidosterolic extract of Ser-
enoa repens inhibits the expression of two key inflammatory
mediators, MCP-1/CCL2 and VCAM-1, in vitro,” BJU Inter-
national, vol. 110, no. 6b, pp. E301–E307, 2012.
[53] D. V. Kouiavskaia, S. Southwood, C. A. Berard, E. N. Klyush-
nenkova, and R. B. Alexander, “T-cell recognition of prostatic
peptides in men with chronic prostatitis/chronic pelvic pain
syndrome,” The Journal of Urology, vol. 182, no. 5, pp. 2483–
2489, 2009.
[54] G. Penna, S. Amuchastegui, C. Cossetti et al., “Spontaneous
and prostatic steroid binding protein peptide-induced autoim-
mune prostatitis in the nonobese diabetic mouse,” Journal of
Immunology, vol. 179, no. 3, pp. 1559–1567, 2007.
[55] S. Ponniah, I. Arah, and R. B. Alexander, “PSA is a candidate
self-antigen in autoimmune chronic prostatitis/chronic pelvic
pain syndrome,” The Prostate, vol. 44, no. 1, pp. 49–54, 2000.
[56] R. S. Matulewicz, A. B. Weiner, and E. M. Schaeffer, “Active
surveillance for prostate cancer,” JAMA, vol. 318, no. 21,
p. 2152, 2017.
[57] F. J. Grant, D. A. Taylor, P. O. Sheppard et al., “Molecular
cloning and characterization of a novel transglutaminase
cDNA from a human prostate cDNA library,” Biochemical
and Biophysical Research Communications, vol. 203, no. 2,
pp. 1117–1123, 1994.
[58] H. G. Williams-Ashman, “Transglutaminases and the clotting
of mammalian seminal fluids,” Molecular and Cellular Bio-
chemistry, vol. 58, no. 1-2, pp. 51–61, 1984.
8 Mediators of Inflammation
[59] M. A. Cukierski, J. L. Sina, S. Prahalada, and R. T. Robertson,
“Effects of seminal vesicle and coagulating gland ablation on
fertility in rats,” Reproductive Toxicology, vol. 5, no. 4,
pp. 347–352, 1991.
[60] D. C. Mukherjee, A. K. Agrawal, R. Manjunath, and A. B.
Mukherjee, “Suppression of epididymal sperm antigenicity in
the rabbit by uteroglobin and transglutaminase in vitro,” Sci-
ence, vol. 219, no. 4587, pp. 989–991, 1983.
[61] G. Paonessa, S. Metafora, G. Tajana et al., “Transglutaminase-
mediated modifications of the rat sperm surface in vitro,” Sci-
ence, vol. 226, no. 4676, pp. 852–855, 1984.
[62] A. Peter, H. Lilja, Å. Lundwall, and J. Malm, “Semenogelin I
and semenogelin II, the major gel-forming proteins in human
semen, are substrates for transglutaminase,” European Journal
of Biochemistry, vol. 252, no. 2, pp. 216–221, 1998.
[63] J. C. Romijn, “Polyamines and transglutaminase actions: Poly-
amine und Transglutaminase-Wirkungen,” Andrologia,
vol. 22, Supplement 1, pp. 83–91, 1990.
[64] N. Landegren, D. Sharon, A. K. Shum et al., “Transglutaminase
4 as a prostate autoantigen in male subfertility,” Science Trans-
lational Medicine, vol. 7, no. 292, article 292ra101, 2015.
[65] S. E. Iismaa, “The prostate-specific protein, transglutaminase 4
(TG4), is an autoantigen associated with male subfertility,”
Annals of Translational Medicine, vol. 4, article S35, Supple-
ment 1, 2016.
[66] H. J. Dubbink, N. S. Verkaik, P. W. Faber, J. Trapman, F. H.
Schröder, and J. C. Romijn, “Tissue specific and androgen-
regulated expression of human prostate-specific transglutami-
nase,” Biochemical Journal, vol. 315, no. 3, pp. 901–908, 1996.
[67] H. J. Dubbink, R. F. Hoedemaeker, T. Van der Kwast,
F. Schröder, and J. C. Romijn, “Human prostate-specific trans-
glutaminase: a new prostatic marker with a unique distribution
pattern,” Laboratory Investigation, vol. 79, no. 2, pp. 141–150,
1999.
[68] G. C. Rivera-Gonzalez, A. P. Droop, H. J. Rippon et al., “Reti-
noic acid and androgen receptors combine to achieve tissue
specific control of human prostatic transglutaminase expres-
sion: a novel regulatory network with broader significance,”
Nucleic Acids Research, vol. 40, no. 11, pp. 4825–4840, 2012.
[69] H. J. Dubbink, L. de Waal, R. van Haperen, N. S. Verkaik,
J. Trapman, and J. C. Romijn, “The human prostate-specific
transglutaminase gene (TGM4): genomic organization,
tissue-specific expression, and promoter characterization,”
Genomics, vol. 51, no. 3, pp. 434–444, 1998.
[70] G. An, C. S. R. Meka, S. P. Bright, and R. W. Veltri, “Human
prostate-specific transglutaminase gene: promoter cloning,
tissue-specific expression, and down-regulation in metastatic
prostate cancer,” Urology, vol. 54, no. 6, pp. 1105–1111, 1999.
[71] G. Davies, R. J. Ablin, M. D. Mason, and W. G. Jiang, “Expres-
sion of the prostate transglutaminase (TGase-4) in prostate
cancer cells and its impact on the invasiveness of prostate can-
cer,” Journal of Experimental Therapeutics & Oncology, vol. 6,
no. 3, pp. 257–264, 2007.
[72] J. L. Thielen, K. G. Volzing, L. S. Collier, L. E. Green, D. A.
Largaespada, and P. C. Marker, “Markers of prostate region-
specific epithelial identity define anatomical locations in the
mouse prostate that are molecularly similar to human prostate
cancers,” Differentiation, vol. 75, no. 1, pp. 49–61, 2007.
[73] W. G. Jiang, R. J. Ablin, H. G. Kynaston, and M. D. Mason,
“The prostate transglutaminase (TGase-4, TGaseP) regulates
the interaction of prostate cancer and vascular endothelial
cells, a potential role for the ROCK pathway,” Microvascular
Research, vol. 77, no. 2, pp. 150–157, 2009.
[74] B. J. Blencowe, “Alternative splicing: new insights from global
analyses,” Cell, vol. 126, no. 1, pp. 37–47, 2006.
[75] M. J. Pajares, T. Ezponda, R. Catena, A. Calvo, R. Pio, and
L. M. Montuenga, “Alternative splicing: an emerging topic in
molecular and clinical oncology,” The Lancet Oncology,
vol. 8, no. 4, pp. 349–357, 2007.
[76] Z. Shaikhibrahim, A. Lindstrot, R. Buettner, and N. Wernert,
“Analysis of laser-microdissected prostate cancer tissues
reveals potential tumor markers,” International Journal of
Molecular Medicine, vol. 28, no. 4, pp. 605–611, 2011.
[77] S. Principe, Y. Kim, S. Fontana et al., “Identification of
prostate-enriched proteins by in-depth proteomic analyses of
expressed prostatic secretions in urine,” Journal of Proteome
Research, vol. 11, no. 4, pp. 2386–2396, 2012.
[78] Y. Kim, V. Ignatchenko, C. Q. Yao et al., “Identification of dif-
ferentially expressed proteins in direct expressed prostatic
secretions of men with organ-confined versus extracapsular
prostate cancer,” Molecular & Cellular Proteomics, vol. 11,
no. 12, pp. 1870–1884, 2012.
[79] R. J. Ablin, S. Owen, and W. G. Jiang, “Prostate transglutami-
nase (TGase-4) induces epithelial-to-mesenchymal transition
in prostate cancer cells,” Anticancer Research, vol. 37, no. 2,
pp. 481–488, 2017.
[80] S. Kumar and K. Mehta, “Tissue transglutaminase, inflamma-
tion, and cancer: how intimate is the relationship?,” Amino
Acids, vol. 44, no. 1, pp. 81–88, 2013.
[81] B. Friedrichs, H. Riedmiller, H. W. Goebel, U. Rausch, and
G. Aumüller, “Immunological characterization and activity
of transglutaminases in human normal andmalignant prostate
and in prostate cancer cell lines,” Urological Research, vol. 23,
no. 5, pp. 301–310, 1995.
[82] S. Chen, F. Lin, S. Iismaa, K. N. Lee, P. J. Birckbichler, and
R. M. Graham, “α1-adrenergic receptor signaling via gh is sub-
type specific and independent of its transglutaminase activity,”
Journal of Biological Chemistry, vol. 271, no. 50, pp. 32385–
32391, 1996.
[83] N. Suto, K. Ikura, and R. Sasaki, “Expression induced by
interleukin-6 of tissue-type transglutaminase in human hepa-
toblastoma HepG2 cells,” Journal of Biological Chemistry,
vol. 268, no. 10, pp. 7469–7473, 1993.
[84] G. S. Kuncio, M. Tsyganskaya, J. Zhu et al., “TNF-αmodulates
expression of the tissue transglutaminase gene in liver cells,”
American Journal of Physiology-Gastrointestinal and Liver
Physiology, vol. 274, no. 2, pp. G240–G245, 1998.
[85] G. Quan, J. Y. Choi, D. S. Lee, and S. C. Lee, “TGF-β1 up-
regulates transglutaminase two and fibronectin in dermal
fibroblasts: a possible mechanism for the stabilization of tissue
inflammation,” Archives of Dermatological Research, vol. 297,
no. 2, pp. 84–90, 2005.
[86] A. P. Mann, A. Verma, G. Sethi et al., “Overexpression of tissue
transglutaminase leads to constitutive activation of nuclear
factor-κB in cancer cells: delineation of a novel pathway,” Can-
cer Research, vol. 66, no. 17, pp. 8788–8795, 2006.
[87] S. S. Park, J. M. Kim, D. S. Kim, I. H. Kim, and S. Y. Kim,
“Transglutaminase 2 mediates polymer formation of I-κBα
through C-terminal glutamine cluster,” Journal of Biological
Chemistry, vol. 281, no. 46, pp. 34965–34972, 2006.
[88] K. S. Park, D. S. Kim, C. Ko, S.-J. Lee, S. H. Oh, and S.-Y. Kim,
“TNF-α mediated NF-kappaB activation is constantly
9Mediators of Inflammation
extended by transglutaminase 2,” Frontiers in Bioscience,
vol. E3, pp. 341–354, 2011.
[89] M. Cummings, “Apoptosis of epithelial cells in vivo involves
tissue transglutaminase upregulation,” The Journal of Pathol-
ogy, vol. 179, no. 3, pp. 288–293, 1996.
[90] R. S. Rittmaster, R. W. Norman, L. N. Thomas, and
G. Rowden, “Evidence for atrophy and apoptosis in the pros-
tates of men given finasteride,” The Journal of Clinical Endocri-
nology & Metabolism, vol. 81, no. 2, pp. 814–819, 1996.
[91] O. J. Hickman, P. Dasgupta, C. Galustian, R. A. Smith, and
A. Vyakarnam, “Cathepsin-L and transglutaminase dependent
processing of ps20: a novel mechanism for ps20 regulation via
ECM cross-linking,” Biochemistry and Biophysics Reports,
vol. 7, pp. 328–337, 2016.
[92] R. L. Eckert, M. L. Fisher, D. Grun, G. Adhikary, W. Xu, and
C. Kerr, “Transglutaminase is a tumor cell and cancer stem cell
survival factor,” Molecular Carcinogenesis, vol. 54, no. 10,
pp. 947–958, 2015.
[93] P. J. Birckbichler, R. B. Bonner, R. E. Hurst, B. L. Bane, J. V.
Pitha, and G. P. Hemstreet, “Loss of tissue transglutaminase
as a biomarker for prostate adenocarcinoma,” Cancer,
vol. 89, no. 2, pp. 412–423, 2000.
[94] B. J. Feldman and D. Feldman, “The development of
androgen-independent prostate cancer,” Nature Reviews Can-
cer, vol. 1, no. 1, pp. 34–45, 2001.
[95] U. Jariwala, J. P. Cogan, L. Jia, B. Frenkel, and G. A. Coetzee,
“Inhibition of AR-mediated transcription by binding of Oct1
to a motif enriched in AR-occupied regions,” Prostate,
vol. 69, no. 4, pp. 392–400, 2009.
[96] V. M. Phatak, S. M. Croft, S. G. Rameshaiah Setty et al.,
“Expression of transglutaminase-2 isoforms in normal human
tissues and cancer cell lines: dysregulation of alternative splic-
ing in cancer,” Amino Acids, vol. 44, no. 1, pp. 33–44, 2013.
[97] T. S. Lai and C. S. Greenberg, “TGM2 and implications for
human disease: role of alternative splicing,” Frontiers in Biosci-
ence, vol. 18, no. 2, pp. 504–519, 2013.
[98] P. Torricelli, M. Caraglia, A. Abbruzzese, and S. Beninati, “γ-
Tocopherol inhibits human prostate cancer cell proliferation
by up-regulation of transglutaminase 2 and down-regulation
of cyclins,” Amino Acids, vol. 44, no. 1, pp. 45–51, 2013.
[99] S. Martucciello, G. Paolella, C. Esposito, M. Lepretti, and
I. Caputo, “Anti-type 2 transglutaminase antibodies as modu-
lators of type 2 transglutaminase functions: a possible patho-
logical role in celiac disease,” Cellular and Molecular Life
Sciences, vol. 75, no. 22, pp. 4107–4124, 2018.
10 Mediators of Inflammation
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
